Voyager Therapeutics (VYGR) Net Cash Flow Growth (1y) (2015 - 2026)
Powered by 
Analysis
Voyager Therapeutics (VYGR) Net Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | -263.05% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -111.96% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 114.92% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -61.56% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 1,842.32% |
| 10 | Voyager Therapeutics | 215.07 Mn | 98.73 Mn | - | 75.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.52% |
| Mar 31, 2026 | -748.94% |
| Dec 31, 2025 | 142.03% |
| Sep 30, 2025 | -89.22% |
| Jun 30, 2025 | 53.97% |
| Mar 31, 2025 | -95.52% |
| Dec 31, 2024 | -1,264.96% |
| Sep 30, 2024 | 120.33% |
| Jun 30, 2024 | -179.55% |
| Mar 31, 2024 | -55.39% |
| Dec 31, 2023 | 68.32% |
| Sep 30, 2023 | -1,066.08% |
| Jun 30, 2023 | 55.49% |
| Mar 31, 2023 | 1,072.87% |
| Dec 31, 2022 | -64.77% |
| Sep 30, 2022 | 390.96% |
| Jun 30, 2022 | -119,673.33% |
| Mar 31, 2022 | 8.09% |
| Dec 31, 2021 | 113.85% |
| Sep 30, 2021 | -303.74% |